United States securities and exchange commission logo

                               May 25, 2021

       Saurabh Saha, M.D., Ph.D.
       Chief Executive Officer
       Centessa Pharmaceuticals plc
       3rd Floor, 1 Ashley Rd.
       Altrincham, Cheshire
       United Kingdom, WA14 2DT

                                                        Re: Centessa
Pharmaceuticals plc
                                                            Amendment No. 2 to
Registration Statement on Form S-1
                                                            Filed May 24, 2021
                                                            File No. 333-255393

       Dear Dr. Saha:

             We have reviewed your amended registration statement and have the
       comments. In some of our comments, we may ask you to provide us with
information so we
       may better understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.

       Amendment No. 2 to Registration Statement on Form S-1 filed May 24, 2021


   1.                                                   The Exhibit 5.1 legal
opinion should not assume conclusions of law or material facts that
                                                        are necessary for the
ultimate opinion. Please revise your legal opinion to remove
                                                        assumptions (g), (j),
(k), and (l) and reservations (a), (c), (d), (e) and (f). For guidance,
                                                        please refer to Section
II.B.3.a of Staff Legal Bulletin No. 19.
   2.                                                   Please file your
Severance and Change in Control Policy as an exhibit to the registration
                                                        statement. See Item
601(b)(10)(iii)(A) of Regulation S-K.
 Saurabh Saha, M.D., Ph.D.
Centessa Pharmaceuticals plc
May 25, 2021
Page 2

       You may contact Tara Harkins at 202-551-3639 or Daniel Gordon at
202-551-3486 if
you have questions regarding comments on the financial statements and related
matters. Please
contact Irene Paik at 202-551-6553 or Joe McCann at 202-551-6262 with any other

FirstName LastNameSaurabh Saha, M.D., Ph.D.
                                                          Division of
Corporation Finance
Comapany NameCentessa Pharmaceuticals plc
                                                          Office of Life
May 25, 2021 Page 2
cc:       Edwin O   Connor - Goodwin Procter LLP
FirstName LastName